A Cross-sectional Study of COPD and Symptom Variability in MEA Countries
NCT ID: NCT03425760
Last Updated: 2018-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3254 participants
OBSERVATIONAL
2015-12-07
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It will also explore the current practice in management of stable GOLD C and D COPD patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00722267
Perception of Symptom Variability in COPD
NCT01753427
Realize the Current Situation of COPD Patients in China
NCT03131362
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
NCT00292552
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
NCT01219946
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Secondary objectives:
* To describe the current treatment practice for the management of GOLD C and D COPD in MEA countries and their adherence to the GOLD 2015 guidelines
* To compare patients' perception of symptoms variability and their impact on activities between Gold categories C and D
* To identify demographic, behavioral and clinical factors associated with symptoms variability.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Stable GOLD C or D COPD patient under maintenance treatment, over 45 years, who provided signed informed consent;
2. COPD diagnosis documented by spirometry performed in the past 12 months with an FEV1/FVC \< 0.7 and an FEV1 \< 50% predicted.
Exclusion Criteria
1. Patient with an ongoing COPD exacerbation\*;
2. Patient who has experienced an exacerbation\* in the previous 3 months;
3. History of asthma, allergic rhinitis, lung cancer or any other significant respiratory disease, such as tuberculosis, lung fibrosis or sarcoidosis;
4. Inability to understand the study related questions;
5. Mentally disabled patient or unable to read and write;
6. Pregnant.
7. Current participation in a clinical trial;
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2287R00105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.